Optymedge
Optymedge is recorded as a service provider in 36 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 36 trials · Latest update first
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma
Sponsor Aura Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
Sponsor 4d Molecular Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
Sponsor Oculis Operations S.a.r.l.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2/3 Double-masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
Sponsor Oculis Operations S.a.r.l.
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)
Sponsor Ideaya Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A phase IIIb, Multicenter, Single-Arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Sponsor Eyepoint Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Sponsor Eyepoint Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
Sponsor Alkeus Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
An open-label, non-randomized, multi-center, phase 4 pharmacokinetic study to evaluate the systemic exposure after bilateral intravitreal administration of high dose (8 mg) aflibercept in adults with diabetic macular edema or neovascular age-related macular degeneration
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)
Sponsor Aura Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase IIIb, Global, Multicenter, Randomized, Visual Assessor−Masked Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (Velodrome)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Masked, Placebo-Controlled Study Assessing the Efficacy and Safety Of Privosegtor (OCS-05) as add-on to IV Methylprednisolone in Participants with Optic Neuritis (PIONEER 1)
Sponsor Oculis Operations SARL
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
Sponsor Priovant Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thyroid Eye Disease
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thyroid Eye Disease
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Optymedge?
The 2026-10-09 snapshot links Optymedge to 36 distinct CTIS trials. Recorded services include Laboratory services, BCDVA Certification, BCVA (Best Corrected Visual Acuity) Iane and technician certification, BCVA VA / Lane Certification, among 33 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Optymedge?
The most frequently recorded therapeutic areas are Ophthalmology, Endocrinology, Solid Tumor Oncology. Recorded phases include Phase 3, Phase 2, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Optymedge conducted?
The linked trials record locations in 21 countries, including Germany, Spain, Italy, France, Czechia. These are trial locations, not confirmed office locations or countries where Optymedge delivered services.
What can this page tell me about Optymedge's trial experience?
Browse 36 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Optymedge. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- OptymEdge
- Optymedge LLC